High-Growth, $10 Million Revenue, Multi-Location Orthotics & Prosthetics Company in the Midwest

American HealthCare Capital is pleased to exclusively introduce an Orthotics & Prosthetics (O&P) Company for sale in the Midwest. This multi-location Prosthetics and Orthotics company provides comprehensive, custom O&P care for patients with custom orthoses, upper and lower extremity prostheses, and utilizes the most advanced technology for its products and services. Its in-house fabrication lab has state-of-the-art scanning and CAD equipment for fabrication of prostheses and orthoses for upper and lower extremities, including microprocessor-controlled prosthetics, bionic, and myoelectric limbs.

This premier company has generated revenue growth of 13.9% Compounded Annual Growth Rates (CAGR) over the past 4 years and is a market leader. It dominates its region with high-quality practitioners and custom services restoring mobility, function, and improving its patients’ lives every day.

Differentiators and Core Competencies

High revenue growth of 13.9% Compound Annual Growth Rate (CAGR) over 4 years

Strong increasing margins of Gross Profit of 68% and Adjusted EBITDA of 19%

All ABC Accredited Facilities

Certified CPOs (Certified Prosthetist Orthotist), CP/LP (Licensed Prosthetist), and LO (Licensed Orthotist)

Complete adult custom orthotic and prosthetic services for upper and lower extremities

Complete pediatric custom orthotic and prosthetic services

In-House Fabrication Lab with state-of-the-art technology fully staffed

Dedicated in-house CPO compliance officer

Product Mix

The Company’s product mix is 68% Prosthetics and 32% Orthotics. The Company’s payer mix consists of 34% Medicare, 33% Commercial Insurance, 12% VA and Nursing Homes, 10% Workers Comp, 10% Medicaid, and 1% Self-pay

Financial Overview

The Company’s revenues over the 4 years from 2022 to 2025 (pro forma) have grown at a compounded annual growth rate (CAGR) of 13.9%, with an increasing Gross Profit that has gone from 61% to 68% and an Adjusted EBITDA of 19%.

Asking Price

The asking price for this multi-location prosthetics and orthotics company is $14.5 million, plus the possibility of an earn-out going forward. This does not include cash, receivables, or working capital.

Rare, $5.8 Million EBITDA, Multi-location Treatment Centers and IOP/OP Opportunity in the Northeast

American Healthcare Capital is proud to exclusively present a leading provider of Residential Treatment Centers, including both intensive outpatient and outpatient programs, all focused on patient recovery, wellness, and care.

Headquartered in the Northeast region of the U.S., this company operates multiple Residential Treatment Centers, plus a new facility ramping up operations in 2025 and doubling the Company’s current capacity (from 200 to over 400 patients).

Financial Overview

The company boasts a well-established and diversified payer mix:

State funding: 65%

County funding: 16%

Medicaid: 16%

Other (including cash): 3%

From 2021 to the forecasted results for 2025, the company has achieved significant revenue growth, rising from $5.2 million to $13.5 million, representing a compound annual growth rate (CAGR) of 21.2%. During the same period, adjusted EBITDA has grown at a notable 46% CAGR, increasing from $890,000 in 2021 to a projected $5.8 million by 2025. The company’s Gross Margin is expected to reach 40% by 2025.

Transition Overview

The company and its leadership team are now at a pivotal point. Since 2021, the company has invested over $5 million to create a de novo facility to double the Company’s capacity. This facility will significantly boost the company’s revenue and profitability by leveraging the higher rates associated with these services. Concurrently, the 100% owner is planning to retire within the next 5 to 6 years. As a result, the owner has decided to explore selling the company and has appointed American Healthcare Capital as the exclusive M&A advisor. The owner is open to various deal structures, including equity roll-over or a full buyout, depending on the buyer’s background and experience in scaling healthcare businesses. In either case, the current owner would consider staying on for up to 5 years post-transaction

Asking Price

The asking price for this opportunity will be determined through further discussion and negotiation.

$5 Million EBITDA Urology Group Practice in Midwest Seeking Strategic or a Capital Partner to Expand   

American Healthcare Capital is proud to be the exclusive representative of a well-established and highly reputable urology practice in the Midwest seeking a strategic or capital partner to support future growth and facilitate a roll up strategy of other Urology groups as well as related specialty services. Founded over two decades ago, this practice has built a strong reputation for delivering advanced urological care through cutting-edge technology and an expert medical team.

Business Overview

Structured as a physician-owned entity, the practice operates with a team of highly skilled providers and a dedicated support staff. The patient base is diverse, with a significant portion covered by Medicare, alongside commercial insurance and Medicaid patients. The practice maintains financial stability, with strong EBITDA performance despite a recent strategic shift away from pharmacy services due to reimbursement changes.

Financial Performance (2022-2025)

Gross revenue has declined over the past few years because of the group’s decision to suspend pharmacy services over time due to changes in insurance reimbursement. However, despite the revenue decline, EBITDA has remained stable and exceeded 30% in recent years, which demonstrates the practice’s ability to sustain strong profitability through cost management and operational efficiency.

RevenueEBITDAMargin %2022$17,428,899$4,406,23425.22023$13,868,926$4,750,36034.252024$13,016,276$4,384,14933.682025$14,300,000$5,005,00035

Note: 2025 numbers are projections and is on track.

Growth Strategy

The practice is well-positioned for expansion through:

Roll Up Strategy: Acquiring other identified targets in Urology and complimentary Specialties

Provider Recruitment: Adding more urologists or licensed nurse practitioners to meet increasing demand.

Geographical Expansion: Entering additional regional markets.

Service Line Expansion: Introducing minimally invasive procedures, robotic surgery, and telemedicine.

Strategic Partnerships: Aligning with hospital networks and insurers.

Technology Investments: Enhancing telemedicine capabilities, Leveraging AI-driven diagnostics and advanced surgical innovations.

Market & Competitive Landscape

The U.S. urology market is growing, fueled by an aging population, increasing prevalence of chronic kidney disease, and advancements in minimally invasive surgical procedures. Market size projections indicate steady expansion, with significant investment potential in specialized urological services and technology-driven care solutions.

Investment Opportunity & Exit Strategy

The current owners are seeking a capital/strategic partner to help them acquire other identified targets and help them scale to become a major platform over the next 5-10 years and preserve their legacy. They are open to a full acquisition or a majority sale with an equity roll-over with an experienced partner.

Conclusion

This practice represents a high-margin, financially stable investment opportunity in the resilient healthcare sector. With its strong patient base, advanced service offerings, and clear expansion strategies, it is an attractive proposition for private equity firms, healthcare investors, or strategic buyers looking to enter or expand in the urology space.

Asking Price and Valuation

The practice is valued at $40 million, with potential deal structures including a 20-25% roll-over equity arrangement and an earnout extending into 2026.

Growing Behavioral Health Provider in Southern California

American HealthCare Capital is pleased to exclusively introduce a leading multi-site behavioral health provider for sale in Southern California. Founded in 2014, the company has evolved into a fully integrated behavioral health system with nearly 100 licensed and affiliated beds, including nearly 24 licensed residential treatment beds, 24 PHP/IOP beds, and 50 long-term transitional housing beds. Its programs span the entire continuum of care from residential treatment and PHP/IOP services to transitional housing and advanced interventions such as ketamine therapy and stellate ganglion block.

What distinguishes the platform is its clinical depth. The company has earned a reputation for successfully treating high-acuity, treatment-resistant psychiatric and dual-diagnosis patients, a population often underserved by other providers. The company is accredited by The Joint Commission, licensed by the State of California, and draws referrals from clinicians, hospitals, alumni, and digital channels, supported by an average rating of 4.85 stars across online platforms.

Financial Performance

Financial performance underscores the strength of the model. The business currently generates an annualized revenue run rate of approximately $14.5 million with EBITDA margins of 22%. With the addition of a new residential facility, revenue is projected to increase to $17.3 million with EBITDA expanding to $4.7 million over the next twelve months.

Exit Strategy

Ownership is offering a 100% equity sale of the parent entity, which manages its clinical affiliates through established agreements, and is open to flexible structures including earn-outs and equity rollover. This represents a rare opportunity to acquire a scaled, clinically sophisticated behavioral health platform with strong profitability, proven scalability, and significant room for continued expansion in one of the most attractive behavioral health markets in the country.

Asking Price

The Asking Price for this business is $22 million, which excludes cash, receivables, and working capital. The owners are open to an earn out, retaining equity and staying on.

2 Memory Care Facilities in the Northeast with 110 Beds

American HealthCare Capital is pleased to exclusively introduce two premier memory care facilities for sale in the northeast. Together, the properties offer 110 licensed beds and consistently maintain full occupancy with wait lists. Both are known for exceptional care, award-winning programs, and strong community referral networks, creating a rare opportunity to acquire fully stabilized, high-demand facilities in a growing market.

Facility Description

The first location is a 60-bed community that serves both private-pay residents (50%) and state-funded residents (50%). The facility specializes in memory care, residential care, respite stays, and adult day programs. Residents benefit from onsite 24/7 licensed nursing, a medical director, and weekly visits from a geriatric psychiatrist, dietitian, and social worker. Flexible, all-inclusive month-to-month pricing ensures families can access services without long-term contracts or unexpected rent increases.The second location is a state-of-the-art memory care community. The facility accommodates 50 private-pay residents in a warm, home-like environment that encourages independence, privacy, and choice. Each unit offers intimate living spaces, family-style kitchens, and secure outdoor courtyards with heated floors for year-round enjoyment.

Financial Overview

The two facilities have shown consistent growth in revenue and profitability over the past four years. Combined, they generated $12.74 million in gross revenue in 2022, which grew to $13.94 million in 2023, $15.67 million in 2024, and is estimated at $15.51 million for 2025. Adjusted EBITDA increased consistently from $2.48 million in 2022 to $3.08 million in 2023, to $4.43 million (28%) in 2024, and is estimated at $4.83 million (31%) in 2025.

Overall, the facilities have demonstrated strong momentum with growing revenue streams and improving EBITDA margins. The combined adjusted EBITDA growth of over 95% from 2022 to the 2025 estimate highlights effective operational management and strong expense control.

Growth Opportunities

Growth opportunities include expanding private-pay services, implementing rate adjustments to align with strong demand, adding adult day and respite care programs, and leveraging brand recognition to enter new markets. The company also holds licensure for 32 additional beds, which could be readily developed on the existing facility and land.

Staff Overview and Exit Plan

Both facilities are supported by a highly experienced, dedicated workforce expected to remain after the transition. While the owners are open to negotiating post-sale involvement, their goal is to move on while ensuring a smooth transition to new ownership.

Asking Price

The asking price for this opportunity is $44.9 million, which includes the real estate. It does not include cash, receivables, or working capital.

$8 Million EBITDA Multi-State ABA Therapy Platform

American HealthCare Capital is pleased to exclusively present an established, multi-state Applied Behavior Analysis (“ABA”) therapy provider for sale. The Company delivers in-home, community-based, and clinic-based therapy to children and adolescents with autism spectrum disorder and related developmental disabilities. Known for its clinical excellence and individualized approach, the platform has developed strong relationships with families, referral sources, and commercial payers across its growing geographic footprint.

The Company serves more than 300 patients annually, with approximately 95 percent of services delivered in-home. This service model creates high levels of family engagement and supports superior clinical outcomes. Therapy is delivered on a one-to-one basis by experienced BCBAs and RBTs, supported by a highly trained management and clinical leadership team. Demand continues to exceed available staffing, underscoring the strength of the brand and the unmet need in its markets.

Payer Relationships

The Company is in-network with many major commercial insurers, including Blue Cross Blue Shield, Aetna, Cigna, Tricare, and several regional carriers. Medicaid participation is limited and represents only a small fraction of total revenue. Recent investments in billing infrastructure and the engagement of a specialized third-party billing partner have significantly improved collections, enhancing both revenue capture and cash flow predictability.

Financial Performance

The platform has demonstrated strong growth and profitability, with revenue increasing from approximately $11.6 million in 2023 to $13.6 million in 2024, while adjusted EBITDA expanded from $4.2 million to $5.4 million over the same period. Through the first eight months of 2025, the Company generated $11.2 million in revenue and $5.5 million of adjusted EBITDA, positioning it to achieve a full-year run-rate of $18 million in revenue and $8 million in EBITDA.

Investment Highlights

This opportunity represents a chance to acquire a premier ABA therapy platform with:

A proven, scalable in-home service model that drives superior outcomes and high patient retention.

Consistently strong financial performance with expanding margins and robust cash flow.

A diversified commercial payer base with minimal Medicaid exposure.

A seasoned leadership team with deep operational and clinical expertise that will remain with the business post-transaction.

Asking Price and Exit Plan

The seller is seeking a full exit at a valuation of $55 million. The seller is open to a transitional role to support integration with new ownership.